Phathom Pharmaceuticals, Inc.
PHAT
$3.31
$0.165.08%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 28.52M | 29.66M | 16.35M | 7.32M | 1.91M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 28.52M | 29.66M | 16.35M | 7.32M | 1.91M |
| Cost of Revenue | 3.72M | 3.82M | 2.36M | 1.38M | 426.00K |
| Gross Profit | 24.80M | 25.85M | 14.00M | 5.95M | 1.49M |
| SG&A Expenses | 94.47M | 76.68M | 76.10M | 75.87M | 62.01M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 107.38M | 89.08M | 87.15M | 84.62M | 71.87M |
| Operating Income | -78.86M | -59.42M | -70.80M | -77.30M | -69.95M |
| Income Before Tax | -94.32M | -74.45M | -85.58M | -91.45M | -82.85M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -94.32M | -74.45M | -85.58M | -91.45M | -82.85M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -94.32M | -74.45M | -85.58M | -91.45M | -82.85M |
| EBIT | -78.86M | -59.42M | -70.80M | -77.30M | -69.95M |
| EBITDA | -78.69M | -59.22M | -70.61M | -77.10M | -69.74M |
| EPS Basic | -1.31 | -1.05 | -1.32 | -1.56 | -1.42 |
| Normalized Basic EPS | -0.82 | -0.66 | -0.83 | -0.98 | -0.89 |
| EPS Diluted | -1.31 | -1.05 | -1.32 | -1.56 | -1.42 |
| Normalized Diluted EPS | -0.82 | -0.66 | -0.83 | -0.98 | -0.89 |
| Average Basic Shares Outstanding | 71.97M | 71.04M | 64.63M | 58.56M | 58.37M |
| Average Diluted Shares Outstanding | 71.97M | 71.04M | 64.63M | 58.56M | 58.37M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |